Morgan Stanley
RDHL

Morgan Stanley’s Redhill Biopharma RDHL Stock Holding History

Morgan Stanley’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 8399
2026
Q1 		$1 Hold
1
– – ﹤0.01% 8282
2025
Q4 		$1 Hold
1
– – ﹤0.01% 8192
2025
Q3 		$2 Sell
1
-1,801
-100% -$2.93K ﹤0.01% 8146
2025
Q2 		$3.5K Buy
1,802
+1,789
+13,762% +$3.65K ﹤0.01% 7122
2025
Q1 		$34 Sell
13
-2,200
-99% -$10.2K ﹤0.01% 7840
2024
Q4 		$13.7K Buy
2,213
+2,033
+1,129% +$15.5K ﹤0.01% 6690
2024
Q3 		$1.57K Buy
180
+166
+1,186% +$1.63K ﹤0.01% 7172
2024
Q2 		$134 Sell
14
-7
-33% -$78 ﹤0.01% 7320
2024
Q1 		$274 Sell
21
-25
-54% -$446 ﹤0.01% 7288
2023
Q4 		$1.68K Buy
46
+30
+188% +$612 ﹤0.01% 7151
2023
Q3 		$205 Sell
16
-8
-33% -$209 ﹤0.01% 7382
2023
Q2 		$721 Buy
24
+7
+41% +$404 ﹤0.01% 7338
2023
Q1 		$1.74K Sell
17
-428
-96% -$80.8K ﹤0.01% 7265
2022
Q4 		$62.5K Buy
445
+58
+15% +$25.1K ﹤0.01% 6193
2022
Q3 		$195K Buy
387
+243
+169% +$212K ﹤0.01% 5739
2022
Q2 		$125K Buy
144
+105
+269% +$144K ﹤0.01% 6155
2022
Q1 		$99K Buy
39
+3
+8% +$7.11K ﹤0.01% 6317
2021
Q4 		$92K Buy
36
+2
+6% +$8K ﹤0.01% 6494
2021
Q3 		$156K Sell
34
-10
-23% -$67.8K ﹤0.01% 6125
2021
Q2 		$301K Buy
44
+25
+132% +$173K ﹤0.01% 5807
2021
Q1 		$137K Sell
19
-2
-10% -$16.8K ﹤0.01% 5859
2020
Q4 		$170K Buy
21
+2
+11% +$18K ﹤0.01% 5670
2020
Q3 		$197K Buy
19
+16
+533% +$131K ﹤0.01% 5130
2020
Q2 		$21K Sell
3
-2
-40% -$13.8K ﹤0.01% 5996
2020
Q1 		$22K Sell
5
-21
-81% -$105K ﹤0.01% 5776
2019
Q4 		$158K Sell
26
-12
-32% -$76.7K ﹤0.01% 5499
2019
Q3 		$266K Sell
38
-46
-55% -$335K ﹤0.01% 4992
2019
Q2 		$547K Sell
84
-22
-21% -$169K ﹤0.01% 4566
2019
Q1 		$877K Buy
106
+23
+28% +$182K ﹤0.01% 4202
2018
Q4 		$462K Buy
83
+57
+219% +$437K ﹤0.01% 4840
2018
Q3 		$230K Buy
26
+23
+767% +$187K ﹤0.01% 5390
2018
Q2 		$25K Buy
3
+1
+50% +$6.36K ﹤0.01% 6097
2018
Q1 		$9K Buy
2
+1
+100% +$5.76K ﹤0.01% 6288
2017
Q4 		$3K Sell
1
-2
-67% -$13.5K ﹤0.01% 6406
2017
Q3 		$28K Sell
3
-2
-40% -$17.8K ﹤0.01% 5950
2017
Q2 		$42K Buy
+5
New +$48.1K ﹤0.01% 5905
2017
Q1 		– Sell
-6
Closed -$59.9K – 6464
2016
Q4 		$58K Hold
6
– – ﹤0.01% 5711
2016
Q3 		$89K Buy
6
+5
+500% +$69.9K ﹤0.01% 5360
2016
Q2 		$11K Sell
1
-5
-83% -$57.8K ﹤0.01% 6044
2016
Q1 		$68K Sell
6
-9
-60% -$94.2K ﹤0.01% 5489
2015
Q4 		$196K Buy
15
+14
+1,400% +$174K ﹤0.01% 5098
2015
Q3 		$10K Hold
1
– – ﹤0.01% 6244
2015
Q2 		$20K Buy
+1
New +$15.9K ﹤0.01% 6138
2015
Q1 		– Hold
0
– – – 6371
2014
Q4 		– Hold
0
– – – 6437
2014
Q3 		– Hold
0
– – – 6644
2014
Q2 		– Hold
0
– – – 6583
2014
Q1 		– Hold
0
– – – 6529

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley's RDHL Position: Q2 2026 in Review

Morgan Stanley held its Redhill Biopharma (RDHL) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #8399.

Morgan Stanley first reported a position in RDHL in Q2 2015 and has held it in 44 quarters since. The position peaked at $877K in Q1 2019. 14 funds tracked by Wall St. Rank hold RDHL as of Q2 2026.

  • Morgan Stanley held 1 share of Redhill Biopharma worth $1 as of Q2 2026.
  • Morgan Stanley left its Redhill Biopharma share count unchanged in Q2 2026.
  • Redhill Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8399 holding.
  • Morgan Stanley first reported a position in Redhill Biopharma in Q2 2015 and has held it in 44 quarters since.
  • Morgan Stanley's Redhill Biopharma position peaked at $877K in Q1 2019.
  • 14 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.